Key Points
- CTO Jay Stout sold 1,977 shares on Jan. 21 at an average price of $26.03 for about $51,461, reducing his stake by 0.99% to 197,634 shares (≈$5.14M).
- Immunovant shares opened at $26.01 (down ~0.6%), trading near a 12‑month high of $27.80 with a 50‑day/200‑day moving average of $25.12/$20.18 and a market cap of ~$4.56 billion (P/E: -9.16).
- Analysts have mixed views but the consensus is a “Moderate Buy” with an average target of $30.78, while hedge funds and institutions have notably increased positions (institutions own ~47.08%).
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CTO Jay Stout sold 1,977 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $26.03, for a total value of $51,461.31. Following the sale, the chief technology officer owned 197,634 shares of the company's stock, valued at approximately $5,144,413.02. This represents a 0.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Immunovant Stock Down 0.6%
Shares of IMVT opened at $26.01 on Friday. The business's fifty day moving average is $25.12 and its 200 day moving average is $20.18. Immunovant, Inc. has a 12-month low of $12.72 and a 12-month high of $27.80. The stock has a market cap of $4.56 billion, a P/E ratio of -9.16 and a beta of 0.57.
Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.01). During the same quarter last year, the company posted ($0.74) EPS. On average, analysts expect that Immunovant, Inc. will post -2.69 EPS for the current year.
Analyst Ratings Changes
IMVT has been the topic of a number of analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Immunovant in a report on Friday, January 9th. JPMorgan Chase & Co. decreased their price objective on Immunovant from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Tuesday, September 30th. Truist Financial raised their target price on Immunovant from $16.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 8th. Wolfe Research raised Immunovant from a "peer perform" rating to an "outperform" rating and set a $50.00 target price on the stock in a research report on Tuesday, January 6th. Finally, The Goldman Sachs Group increased their price target on Immunovant from $18.00 to $28.00 and gave the company a "neutral" rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $30.78.
Check Out Our Latest Research Report on IMVT
Hedge Funds Weigh In On Immunovant
Hedge funds and other institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC increased its position in shares of Immunovant by 319.0% during the third quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company's stock valued at $36,137,000 after acquiring an additional 1,706,687 shares during the last quarter. Norges Bank bought a new position in Immunovant in the 2nd quarter valued at $11,003,000. Armistice Capital LLC increased its position in shares of Immunovant by 12.2% during the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company's stock valued at $94,076,000 after purchasing an additional 636,000 shares during the last quarter. Two Seas Capital LP increased its position in shares of Immunovant by 37.1% during the 2nd quarter. Two Seas Capital LP now owns 2,252,772 shares of the company's stock valued at $36,044,000 after purchasing an additional 610,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Immunovant by 2,086.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 463,600 shares of the company's stock worth $7,418,000 after purchasing an additional 442,400 shares during the period. Hedge funds and other institutional investors own 47.08% of the company's stock.
Immunovant Company Profile
(
Get Free Report)
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
